Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
321-340 of 998 trials

Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

Solid and Hematological Malignancies>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncologyRheumatology

Prostate Cancer: uPAR PET Imaging Study

We are investigating a new imaging method to help classify prostate cancer grades in men with localized, untreated disease. This study aims to assess the safety and effectiveness of this non-invasive technique.

Prostate Cancer≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Chronic Immune Thrombocytopenia: Kedrion IVIg Treatment

We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.

Chronic Immune Thrombocytopenia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Scleroderma-Related Lung Disease: Investigational Treatments

We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.

Interstitial Lung Disease due to Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonologyRheumatology

MOGAD: Evaluating Satralizumab Treatment

We are studying the effectiveness and safety of satralizumab for patients with MOGAD. This trial compares the new treatment to a placebo to see how well it prevents disease relapses.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteNeurologyRheumatology

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNephrology

Ulcerative Colitis: Adalimumab Treatment Comparison

We are comparing a new treatment approach with telemonitoring and education to standard care for patients starting adalimumab. The aim is to see if this helps manage ulcerative colitis more effectively.

Ulcerative Colitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

ACP-204 for Alzheimer's Disease Psychosis

We are testing the effects of ACP-204 in adults with Alzheimer's disease psychosis to see if it helps improve symptoms compared to a placebo.

Alzheimer's DiseaseAlzheimer's Disease Psychosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

HER2-Low Metastatic Breast Cancer: DB-1303 vs Chemotherapy

We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.

Hormone Receptor Positive Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Alzheimer's Disease Psychosis: ACP-204 Study

We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.

Alzheimer's Disease Psychosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Pulmonary Fibrosis: Long-Term Study of BI 1015550

We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Pancreatic Cancer: Testing Enzyme Therapy

We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.

Pancreatic Exocrine Insufficiency6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Generalized Myasthenia Gravis: Efgartigimod Safety Study

We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.

Myasthenia GravisEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Long-Term Safety Study of NTLA-2001

We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.

Hereditary Amyloidosis>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

COVID-19 Treatment: RECOVERY Trial

We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.

Pneumonia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Penile Rehabilitation After Prostate Cancer Surgery: PEHAB II

We are studying two approaches to help men regain erections after nerve-sparing prostate surgery. The goal is to see which method leads to better sexual function and quality of life.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteUrology